Navigation Links
"Tomorrow's Health" TV Series Showing the Life Science Industry's Quest to Save and Improve Lives, to Air on Select NBC Stations

SAN DIEGO, Nov. 7, 2011 /PRNewswire/ -- BIOCOM, the trade group representing Southern California's life science industry, and award-winning Phase 3 Digital have partnered to tell the biotechnology story from discovery through development. Consumers across the U.S. will soon get a glimpse into the exciting and innovative world of medical discovery that brings life-saving therapies, medical devices and diagnostics to patients around the globe. "Tomorrow's Health," a new television series created in partnership with the life sciences industry, explores some of the most exciting and promising new treatments under development.

"Tomorrow's Health" introduces viewers to patients, their doctors, and their struggle to achieve healthier lives. The program reveals the surprising truth about the challenges and obstacles biomedical researchers face in the development of cures and bringing new medicines, medical devices and diagnostics to market.

Created and produced by Phase 3 Digital, in partnership with BIOCOM, "Tomorrow's Health" will run on select NBC stations and other major network and cable channels in top media markets around the U.S. The program will feature a website and social media portals, where consumers can view episodes on demand and gain more information on companies and the featured experts.

For more information on how to be considered as a featured company, sponsorship opportunities, or other information contact Ed Personius at Phase 3 Digital, at (714) 748-0600.

Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
2. Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China
3. Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals New Publication Series; Essential Deal Trends
4. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
5. Creabilis Raises €15M ($20M) in Series B Fundraising Round
6. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
7. SironRX Therapeutics Raises $3.4 Million Series A
8. Peloton Therapeutics Completes $18 Million Series A Financing
9. Health Diagnostic Laboratory Inc. Sponsors Lecture Series in West Palm Beach, Florida
10. Northwest Biotherapeutics Announces Series of Financing Arrangements
11. Naurex Completes $18 Million Series A Financing
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, ... (ECNR) in Vienna, Austria to ... Congress of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ... of its Internet-delivered NovaVision Therapy Suite at the 3rd ...
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
Breaking Biology News(10 mins):